A frustrating effort to independently verify claims that Roche's Tamiflu lessens complications from the flu drove postdoctoral fellow Peter Doshi to become a leading advocate for open access to all clinical trial results. Despite some industry resistance, Doshi and his fellow advocates are making gains. GlaxoSmithKline recently promised to share data from all clinical trials since 2000, and the European Medicines Agency is developing a policy opening access to trial data for all approved drugs.

Related Summaries